Morgan Stanley
BIOA

Morgan Stanley’s BioAge Labs BIOA Stock Holding History

Morgan Stanley’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.55M Sell
259,869
-51,790
-17% -$997K ﹤0.01% 4210
2025
Q4 		$4.12M Buy
311,659
+83,501
+37% +$740K ﹤0.01% 4328
2025
Q3 		$1.34M Buy
228,158
+14,655
+7% +$68.6K ﹤0.01% 5009
2025
Q2 		$882K Buy
213,503
+183,877
+621% +$741K ﹤0.01% 5168
2025
Q1 		$111K Sell
29,626
-413,327
-93% -$1.91M ﹤0.01% 5957
2024
Q4 		$2.56M Buy
442,953
+440,644
+19,084% +$7.6M ﹤0.01% 4532
2024
Q3 		$48K Buy
+2,309
New +$46.3K ﹤0.01% 6231

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Morgan Stanley's BIOA Position: Q1 2026 in Review

Morgan Stanley reduced its BioAge Labs (BIOA) stake by 17% in Q1 2026, selling an estimated $997K and leaving 259,869 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

Morgan Stanley first reported a position in BIOA in Q3 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Morgan Stanley held 259,869 shares of BioAge Labs worth $4.55M as of Q1 2026.
  • Morgan Stanley sold 51,790 BioAge Labs shares in Q1 2026, an estimated $997K.
  • BioAge Labs made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4210 holding.
  • Morgan Stanley first reported a position in BioAge Labs in Q3 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.